You are here: Industry Insights > Monoclonal Antibodies

News List

Drug Marketing in China and Worldwide (September)(2023) PharmaSources
October 01, 2023
For the importance of disease monoclonal antibodies, the drug ingredient is still being tested.
Monoclonal Antibodies - The Challenges in Drug Development Neeta Ratanghayra
July 28, 2020
Monoclonal antibodies (mAb) are approved in a wide range of conditions and represent the largest class of biotherapeutic products. mAbs are large molecules with complex structures and functions.
COVID-19 - Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose WorldPharmaNews
January 10, 2022
The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant within a few weeks or months.
New study adds more evidence for Omicron immune evasion WorldPharmaNews
December 27, 2021
A new study from Columbia researchers, in collaboration with scientists at the University of Hong Kong, S.A.R., China, adds more evidence that the omicron variant can evade the immune protection conferred by vaccines...
Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodies prnasia
November 23, 2020
The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have announced their plans to form a strategic partnership in the field of immuno-oncology research.
Quick Look at the Anti-epidemic Monoclonal Antibodies that Target the Novel Coronavirus S Protein PharmaSources/Xiaoyaowan
March 17, 2020
The General Office of the National Health Commission and the Office of the National Administration of Traditional Chinese Medicine of China issued the COVID-19 Diagnosis and Treatment Scheme (Trial Version 6) on Feb. 19. It's worth noting that the scheme
Sales of Toripalimab and Sintilimab Both Exceeded RMB300 Million PharmaSources/Xiaoyaowan
October 24, 2019
Junshi Biosciences’ toripalimab and Innovent’s sintilimab were successively approved in Dec. 2018, to become the first Chinese-produced anti-PD-1 monoclonal antibodies marketed.
Vect-Horus and Janssen partner for neurodegenerative disease treatment SHARE pharmaceutical-technology
December 13, 2018
Vect-Horus has entered a research collaboration agreement with Johnson & Johnson subsidiary Janssen Pharmaceuticals for treating neurodegenerative diseases.....
Amazing Monthly Sales Performance of Opdivo and Keytruda in China Xiaoyaowan
November 06, 2018
It was revealed that by September 30, i.e., about one month after the marketing in China, the sales revenue of the two anti-PD-1 monoclonal antibody drugs: Opdivo and Keytruda separately reached RMB 190 million and RMB 150 million, showing amazing perform
BIOCAD, SPH to build drug substance manufacturing facility in China biospectrumasia
September 17, 2018
These Russian-Chinese joint ventures will be established with the main purpose of development, manufacturing, authorization, and marketing of at least six BIOCAD products.

Previous page 1 2 Next page